Key facts
- It has raised $115.5M across 4 recorded rounds; the latest was Later Stage VC (Series C) ($115.5M) in Oct 2024.
- Evommune has filed 4 Form Ds with the SEC, most recently Jan 2025 ($57.5M sold to 16 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Evommune
Create free account
No card required
Funding rounds
4 roundsOct 2024Later Stage VC (Series C)$115.5M▮
About Evommune
- Industry
- Drug Discovery
PA Mark — not yet priced
Evommune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Evommune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Evommune in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.